Content Hub
Blind Attendee List
An Exclusive Speaker Interview With
Marco Weinberg, Senior Vice President, Head of Research, ReCode Therapeutics
ReCode Therapeutics is a clinical-stage genetic medicines company developing and applying their selective organ targeting (SORT) lipid nanoparticle (LNP) delivery platform to mRNA and gene correction therapeutics and enable precise delivery to target organs and cells beyond the liver.
Read our interview with Marco for an insight into recent developments with applying SORT to extrahepatic indications, as well as his thoughts more broadly on recent developments in editing and delivery technologies within the gene therapy field.
An Exclusive Speaker Interview With..
Jeff Cehelsky, Vice President, Development Operations, Intellia Therapeutics
Intellia Therapeutics are a clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics that leverage CRISPR-based technologies.
Watch our exclusive interview to uncover the key challenges of translating exciting R&D into viable clinical programs, running gene editing clinical trials, and the importance of multistakeholder collaboration to progress the field.